Quick Answer
Theravance Biopharma, Inc. reported Cash and Equivalents of $167.81 million for fiscal year 2025.
Theravance Biopharma, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $167.81M | +344.0% |
| 2024 | $37.80M | -4.4% |
| 2023 | $39.55M | -86.7% |
| 2022 | $298.17M | +231.5% |
| 2021 | $89.96M | +10.4% |
| 2020 | $81.47M | +40.3% |
| 2019 | $58.06M | -84.6% |
| 2018 | $378.02M | +324.8% |
| 2017 | $88.98M | -74.2% |
| 2016 | $344.71M | +205.8% |
| 2015 | $112.71M | +26.3% |
| 2014 | $89.22M | -67.9% |
| 2014 | $277.54M | — |
| 2013 | $0.00 | — |
| 2012 | $0.00 | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $174.77M | +647.6% | -38.0% |
| June 30, 2025 | $281.93M | +508.3% | +154.9% |
| March 31, 2025 | $110.61M | +105.5% | +192.7% |
| December 31, 2024 | $37.80M | -4.4% | +61.7% |
| September 30, 2024 | $23.38M | -67.4% | -49.6% |
| June 30, 2024 | $46.34M | -56.1% | -13.9% |
| March 31, 2024 | $53.84M | -71.3% | +36.1% |
| December 31, 2023 | $39.55M | -86.7% | -44.8% |
- Theravance Biopharma, Inc. showed an increase of +344.0% in Cash and Equivalents compared to the prior fiscal year.
- The most recent figure is from Theravance Biopharma, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 23, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: